dysrhythmias
... tachyrhythms. What is normal for one person may be fatal to another. 2. Documentation of dysrhythmias is extremely important. Field treatment of a dysrhythmia may be life-saving, but long-term treatment requires knowing what the problem was. Documentation also allows for learning and discussion afte ...
... tachyrhythms. What is normal for one person may be fatal to another. 2. Documentation of dysrhythmias is extremely important. Field treatment of a dysrhythmia may be life-saving, but long-term treatment requires knowing what the problem was. Documentation also allows for learning and discussion afte ...
PAC 11 Cardiovascular Diseases II
... The student will continue to learn the structure and function the cardiovascular system as it pertains to human health and disease as a continuation of PAC 03 Cardiology 1. Emphasis is placed on concepts essential to screen for, prevent, diagnose and treat common cardiovascular conditions. Specifica ...
... The student will continue to learn the structure and function the cardiovascular system as it pertains to human health and disease as a continuation of PAC 03 Cardiology 1. Emphasis is placed on concepts essential to screen for, prevent, diagnose and treat common cardiovascular conditions. Specifica ...
Comment - Cardiac Arrhythmias
... ventricular tachycardias (AV-nodal re-entry and atrioventricular re-entry) has proven highly effective. In 1998, it was reported that atrial fibrillation was usually triggered by atrial tachycardias arising from sleeves of atrial tissue extending from the left atrium and wrapping around the pulmona ...
... ventricular tachycardias (AV-nodal re-entry and atrioventricular re-entry) has proven highly effective. In 1998, it was reported that atrial fibrillation was usually triggered by atrial tachycardias arising from sleeves of atrial tissue extending from the left atrium and wrapping around the pulmona ...
this PDF file - Pacific Group of e
... cleft in the anterior leaflet of the mitral valve, but they may occur in isolation. This is sometimes termed a partial AV canal defect or a partial AV septal defect. In this case, a 5-leaflet AV valve is arranged so that separate right and left components (a tricuspid valve and a mitral valve) are p ...
... cleft in the anterior leaflet of the mitral valve, but they may occur in isolation. This is sometimes termed a partial AV canal defect or a partial AV septal defect. In this case, a 5-leaflet AV valve is arranged so that separate right and left components (a tricuspid valve and a mitral valve) are p ...
left coronary artery
... small catheter introduced through the skin into an artery in either the groin or the arm. Assistance of a fluoroscope (a special x-ray viewing instrument), the catheter is then advanced to the opening of the coronary arteries (the blood vessels supplying blood to the heart). The images that are prod ...
... small catheter introduced through the skin into an artery in either the groin or the arm. Assistance of a fluoroscope (a special x-ray viewing instrument), the catheter is then advanced to the opening of the coronary arteries (the blood vessels supplying blood to the heart). The images that are prod ...
Acute Coronary Syndromes
... initially in all patients (without contraindication) followed by oral beta blockers with the goal being decrease in heart rate to 60 beats per minute • A combination of beta blockers and nitrates can be viewed as first line therapy in all patients with ACS ...
... initially in all patients (without contraindication) followed by oral beta blockers with the goal being decrease in heart rate to 60 beats per minute • A combination of beta blockers and nitrates can be viewed as first line therapy in all patients with ACS ...
How to best to counteract the enemies? By blocking neurohormonal activation
... significant benefit, with prolonged survival and improved morbidity in patients with systolic left ventricular dysfunction, and both patients with ischaemic and those with non-ischaemic heart disease. In fact, at present, the treatment of choice in such patients is blockade of both the RAAS and the ...
... significant benefit, with prolonged survival and improved morbidity in patients with systolic left ventricular dysfunction, and both patients with ischaemic and those with non-ischaemic heart disease. In fact, at present, the treatment of choice in such patients is blockade of both the RAAS and the ...
Malnutrition and Left Ventricular Systolic Function in Hospitalized
... 5 million persons in the United States have HF, with more than 550000 new patients diagnosed each year [1-3]. As a result of population ageing and better medical care that contribute to longer life expectancy, HF occurs more and more frequently in the elderly. It is now well established that malnutr ...
... 5 million persons in the United States have HF, with more than 550000 new patients diagnosed each year [1-3]. As a result of population ageing and better medical care that contribute to longer life expectancy, HF occurs more and more frequently in the elderly. It is now well established that malnutr ...
sample PowerPoint presentation on the heart
... I already knew that the muscle of your muscle is called the myocardium. Most of the myocardium is located in the ventricles which are roughly the size of your fist. The porcine heart, like a human heart, has four chambers and four valves. Blood flows through the pig heart in the same manner as throu ...
... I already knew that the muscle of your muscle is called the myocardium. Most of the myocardium is located in the ventricles which are roughly the size of your fist. The porcine heart, like a human heart, has four chambers and four valves. Blood flows through the pig heart in the same manner as throu ...
10. Behçet`s Disease and the Heart
... stopped if symptoms of heart failure develop. (Please note: this is not a comprehensive list of drugs that may affect the heart. Sometimes drugs with a risk of heart side effects may nevertheless be the best choice to treat Behçet’srelated heart disease.) Investigations Initial investigations of sus ...
... stopped if symptoms of heart failure develop. (Please note: this is not a comprehensive list of drugs that may affect the heart. Sometimes drugs with a risk of heart side effects may nevertheless be the best choice to treat Behçet’srelated heart disease.) Investigations Initial investigations of sus ...
high total leukocyte count and heart failure after myocardial infarction
... particular attention was given for the evaluation of sign and symptoms of heart failure during admission and subsequently repeated after every 12 hours for the next four days of hospitalization. Four days was chosen as our cutoff because we believed that after this time the development of CHF may be ...
... particular attention was given for the evaluation of sign and symptoms of heart failure during admission and subsequently repeated after every 12 hours for the next four days of hospitalization. Four days was chosen as our cutoff because we believed that after this time the development of CHF may be ...
NT-proBNP reflects right ventricular structure and function in pulmonary hypertension
... impaired function. Compared with earlier studies [7, 8, 18], the present study showed similar, but modest, correlations of NT-proBNP and haemodynamics. In addition, NT-proBNP was related to RV end-diastolic volume index and showed a strong inverse relationship with RV ejection fraction. The relation ...
... impaired function. Compared with earlier studies [7, 8, 18], the present study showed similar, but modest, correlations of NT-proBNP and haemodynamics. In addition, NT-proBNP was related to RV end-diastolic volume index and showed a strong inverse relationship with RV ejection fraction. The relation ...
Cardiogenic Shock + Critical Aortic Stenosis = Run the Other Way?!!!
... Protocol development for Palliative Care Consults on critically ill AS patients undergoing evaluation for TAVR Palliative Care Consult on all patients in Cardiogenic ...
... Protocol development for Palliative Care Consults on critically ill AS patients undergoing evaluation for TAVR Palliative Care Consult on all patients in Cardiogenic ...
S0735109713055897_mmc1
... studies were performed in left lateral decubitus, using a commercially available imaging system (IE 33, Philips, Andover, MA, USA) equipped with a S5 1- to 5-MHz phased array transducer (Philips, Andover, MA, USA). Each patient underwent standard M-mode, two-dimensional, and Doppler echocardiographi ...
... studies were performed in left lateral decubitus, using a commercially available imaging system (IE 33, Philips, Andover, MA, USA) equipped with a S5 1- to 5-MHz phased array transducer (Philips, Andover, MA, USA). Each patient underwent standard M-mode, two-dimensional, and Doppler echocardiographi ...
Good Samaritan Hospital Leading the Way in Cardiac Innovation
... Hospital. “Traffic on the island can ma ke travel to Roslyn especia lly stressful for patients who require openheart surgery and their loved ones, so we extended the reach of our program. We had already established a working relationship between St. Francis Ho s pit a l a n d G o o d S a m a r it a ...
... Hospital. “Traffic on the island can ma ke travel to Roslyn especia lly stressful for patients who require openheart surgery and their loved ones, so we extended the reach of our program. We had already established a working relationship between St. Francis Ho s pit a l a n d G o o d S a m a r it a ...
Sudden Cardiac Death in a 30-Year
... has been described. 4 Our patient demonstrated marked left ventricular dysfunction in the setting of only modest right ventricular hypokinesia. While this may represent an unusual presentation of ARVC primarily involving the left ventricle, these findings may also have been the result of global isch ...
... has been described. 4 Our patient demonstrated marked left ventricular dysfunction in the setting of only modest right ventricular hypokinesia. While this may represent an unusual presentation of ARVC primarily involving the left ventricle, these findings may also have been the result of global isch ...
Impact of Severe Tricuspid Regurgitation on Long Term Survival
... Materials and Methods: Between 2002 and 2012, 358 consecutive patients (mean age of 54.67± 13.25years, 75.5% female) with severe TR based on history and transthoracic echocardiography (TTE) were enrolled. Patients with severe left sided valvular heart disease and congenital heart disease were exclud ...
... Materials and Methods: Between 2002 and 2012, 358 consecutive patients (mean age of 54.67± 13.25years, 75.5% female) with severe TR based on history and transthoracic echocardiography (TTE) were enrolled. Patients with severe left sided valvular heart disease and congenital heart disease were exclud ...
Cardiovascular failure, inotropes and vasopressors
... Clinical assessment facilitates recognition of subtle indicators of poor perfusion. The exact findings will vary depending on the underlying cause of shock. Inadequate perfusion will impact on the function of vital organs, for example reduced renal perfusion will reduce renal output and poor brain p ...
... Clinical assessment facilitates recognition of subtle indicators of poor perfusion. The exact findings will vary depending on the underlying cause of shock. Inadequate perfusion will impact on the function of vital organs, for example reduced renal perfusion will reduce renal output and poor brain p ...
Lethal outcomes in patients with symptomatic heart failure
... The duration from the occurrence of MI to death was 4 months to 22 years, on the average, 7.1±4.7 years (Fig. 1). Symptomatic CHF occurred 4 months to 17 years after Q-wave MI, on the average, within 5.9±4.7 years. Death occurred after 1 month to 5 years (on the average, 1.5±1.1 years) after the dia ...
... The duration from the occurrence of MI to death was 4 months to 22 years, on the average, 7.1±4.7 years (Fig. 1). Symptomatic CHF occurred 4 months to 17 years after Q-wave MI, on the average, within 5.9±4.7 years. Death occurred after 1 month to 5 years (on the average, 1.5±1.1 years) after the dia ...
Assessment of the Cardiovascular System
... “On regaining consciousness, did you know where you were and who people were around you?” ...
... “On regaining consciousness, did you know where you were and who people were around you?” ...
Angina Patients With Diastolic Versus Systolic Heart Failure
... failure were examined from the International EECP Patient Registry (IEPR) based at the Epidemiology Data Center of the University of Pittsburgh Graduate School of Public Health. The IEPR is a prospective registry formed to determine the patterns of use, safety, and efficacy of EECP. It tracks sequen ...
... failure were examined from the International EECP Patient Registry (IEPR) based at the Epidemiology Data Center of the University of Pittsburgh Graduate School of Public Health. The IEPR is a prospective registry formed to determine the patterns of use, safety, and efficacy of EECP. It tracks sequen ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.